Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Treasury Shares (2016 - 2024)

Historic Treasury Shares for Catalyst Pharmaceuticals (CPRX) over the last 9 years, with Q4 2024 value amounting to $708960.0.

  • Catalyst Pharmaceuticals' Treasury Shares fell 1702.82% to $708960.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $708960.0, marking a year-over-year decrease of 1702.82%. This contributed to the annual value of $708960.0 for FY2024, which is 1702.82% down from last year.
  • As of Q4 2024, Catalyst Pharmaceuticals' Treasury Shares stood at $708960.0, which was down 1702.82% from $854459.0 recorded in Q4 2023.
  • In the past 5 years, Catalyst Pharmaceuticals' Treasury Shares ranged from a high of $1.0 million in Q4 2022 and a low of -$2.2 million during Q4 2021
  • For the 5-year period, Catalyst Pharmaceuticals' Treasury Shares averaged around $30981.6, with its median value being $235671.0 (2020).
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Treasury Shares crashed by 103702.32% in 2021, and later surged by 14528.39% in 2022.
  • Catalyst Pharmaceuticals' Treasury Shares (Quarter) stood at $235671.0 in 2020, then plummeted by 1037.02% to -$2.2 million in 2021, then soared by 145.28% to $1.0 million in 2022, then dropped by 14.55% to $854459.0 in 2023, then dropped by 17.03% to $708960.0 in 2024.
  • Its Treasury Shares was $708960.0 in Q4 2024, compared to $854459.0 in Q4 2023 and $1.0 million in Q4 2022.